首页|期刊导航|中华医学杂志（英文版）|Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis:A post hoc analysis of the JADE REGIMEN phase 3 trial

Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis:A post hoc analysis of the JADE REGIMEN phase 3 trial

Hang Li Shiqi Li Hao Cheng Qianjin Lu Wei Lai Xiaohua Tao Gerardo A.Encinas Shefali Vyas Bo Wang Xin Luo

中华医学杂志（英文版）2024，Vol.137Issue(16)：1991-1992,2.

中华医学杂志（英文版）2024，Vol.137Issue(16)：1991-1992,2.DOI:10.1097/CM9.0000000000003159

Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis:A post hoc analysis of the JADE REGIMEN phase 3 trial

Hang Li ¹Shiqi Li ²Hao Cheng ³Qianjin Lu ⁴Wei Lai ⁵Xiaohua Tao ⁶Gerardo A.Encinas ⁷Shefali Vyas ⁸Bo Wang ⁹Xin Luo¹⁰

作者信息

1. Department of Dermatology,Peking University First Hospital,National Clinical Research Center for Skin and Immune Diseases,Beijing 100034,China
2. Pfizer PBG,Shanghai 200041,China
3. Department of Dermatology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou,Zhejiang 310016,China
4. Department of Dermatology,The Second Xiangya Hospital of Central South University,Changsha,Hunan 410011,China
5. Department of Dermatology,The Third Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510630,China
6. Department of Dermatology,Zhejiang Provincial People's Hospital,Hangzhou Medical College,Hangzhou,Zhejiang 310014,China
7. Pfizer S.A.de C.V.,Mexico City,Mexico
8. Pfizer Inc.,New York,NY,USA
9. Pfizer Investment Co.,Ltd,Beijing 100010,China
10. Pfizer(China)R&D Co.,Ltd,Shanghai 201200,China
折叠

摘要

引用本文复制引用

Hang Li,Shiqi Li,Hao Cheng,Qianjin Lu,Wei Lai,Xiaohua Tao,Gerardo A.Encinas,Shefali Vyas,Bo Wang,Xin Luo..Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis:A post hoc analysis of the JADE REGIMEN phase 3 trial[J].中华医学杂志（英文版）,2024,137(16):1991-1992,2.

基金项目

Editorial and writing support was provided by Apoth-eCom under the direction of authors,and in accordance guidelines from the American Medical Writers Association,European Medical Writers Association,and International Society for Medical Publication Professionals,and was funded by Pfizer Inc.,New York,NY,USA,in accordance with Good Publication Practice(GPP 2022)guidelines(Ann Intern Med.2022 （GPP 2022）

10.7326/M22-1460). （）

中华医学杂志（英文版）

OACSTPCDMEDLINE

ISSN：0366-6999

访问量0

下载量0

段落导航